-

Qnovia to Present at Gilmartin Group Private Company Showcase

RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas, announced today that Brian Quigley, CEO, will give a corporate presentation at Gilmartin Group’s inaugural virtual Spring Private Company Showcase. The company will present on Tuesday, April 18, 2023, at 4:00pm ET.

To attend the presentation, please register using this link.

About Qnovia, Inc.

Qnovia, Inc., formerly Respira Technologies, Inc., is a pharma company focused on developing and commercializing proprietary inhalation device technologies to improve patient outcomes. The company’s drug delivery platform is the first orientation-agnostic, portable vibrating mesh nebulizer that effectively operates in any position held by the patient. Qnovia sees significant opportunity to utilize its drug delivery technologies to improve the treatment of asthma, COPD, vaccine delivery, pain management, and several generic as well as select investigational new drugs. The company was founded by Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies. The company can be found at www.qnovia.com.

Contacts

Investor Relations:
Kiki Patel, PharmD
Gilmartin Group, Principal
Kiki@gilmartinir.com

Media Relations:
Richard Laermer
CEO
RLM Public Relations
212-741-5106 X 216
Qnovia@RLMpr.com

Qnovia, Inc.


Release Versions

Contacts

Investor Relations:
Kiki Patel, PharmD
Gilmartin Group, Principal
Kiki@gilmartinir.com

Media Relations:
Richard Laermer
CEO
RLM Public Relations
212-741-5106 X 216
Qnovia@RLMpr.com

More News From Qnovia, Inc.

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxTM, today announced the appointment of four new members to its Scientific Advisory Board (SAB). The new members include Neal Benowitz, MD, Professor at University of California at San Francisco, Ian M. Fearon, PhD, independent consultant, Darla E. Kendzor, PhD, Professor at University of...

Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy

RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxTM, today announced positive results from its first in-human study of QN-01, the company’s lead asset. QN-01 is an inhaled smoking cessation therapy that is currently being evaluated in the U.S. under FDA’s Center for Drug Evaluation and Research (CDER) and in the U.K. by the Medicines and Health...

Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases

RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas, today announced it has entered into a drug development collaboration with the University of Virginia (UVA) to advance novel inhaled-drug candidates for treating bacterial infections in the lungs. Qnovia will work with UVA School of Medicine investigators Dr. Molly Hughes and Dr. Matthew Crawford to combine Qnovia’s RespiRxTM inhaled drug delivery platform and UVA’...
Back to Newsroom